Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Marksans PharmaBOM:524404 +0.50%86 Pretax Margin % is 23.36% as of Mar. 2026, which is 34% above its 10-year median of 17.49. GuruFocus rates BOM:524404 with a GF Score™ of 86/100 and a GF Value™ of ₹229.14 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 961 Drug Manufacturers companies, Marksans Pharma ranks better than 79.29% on this metric.
The historical rank and industry rank for Marksans Pharma's Pretax Margin % or its related term are showing as below:
BOM:524404'
s Pretax Margin % Range Over the Past 10 Years
Min: 1.96 Med: 17.49 Max: 22.08
Current: 19
BOM:524404's Pretax Margin % is ranked better than 79.29% of 961
companies
in the Drug Manufacturers industry
Industry Median: 7.28
vs BOM:524404: 19.00
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Marksans Pharma Pretax Margin % Related Terms
Marksans Pharma Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Marksans Pharma's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524404 vs LLY, JNJ, ABBV: Pretax Margin % Comparison
For the Drug Manufacturers - General subindustry, Marksans Pharma's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Marksans Pharma Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Marksans Pharma's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Marksans Pharma's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Marksans Pharma (BOM:524404) has a Pretax Margin % of 23.36% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Marksans Pharma and its competitors. This is 34% above median its historical median of 17.49. Over the past decade, Marksans Pharma's Pretax Margin % has ranged from 1.96 to 22.08. According to the industry distribution chart, Marksans Pharma ranks #199 out of 961 companies in the Drug Manufacturers industry, placing it in the top 20.7%.
Is Marksans Pharma's Pretax Margin % too high?
Marksans Pharma's current Pretax Margin % of 23.36% is 34% above median its 10-year median of 17.49. Over the past 10 years, this metric has ranged from a low of 1.96 to a high of 22.08. The Drug Manufacturers industry median Pretax Margin % is 7.28. Marksans Pharma's value of 23.36% is 220.9% above this industry median. Based on the distribution chart, Marksans Pharma ranks #199 out of 961 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Marksans Pharma has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Marksans Pharma's Pretax Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Marksans Pharma ranks #199 out of 961 companies for Pretax Margin %. This places Marksans Pharma in the top 21% of its industry — outperforming the majority of peers. The industry median Pretax Margin % is 7.28. Marksans Pharma's value of 23.36% is 220.9% above this benchmark. Historically, Marksans Pharma's own Pretax Margin % has ranged from 1.96 to 22.08 over the past decade. While the company's 10-year median is 17.49 vs. the industry median of 7.28, Marksans Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.28, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Marksans Pharma's current Pretax Margin % of 23.36% is 220.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Marksans Pharma and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Marksans Pharma's current Pretax Margin % is 23.36%, which is 34% above median its own 10-year median of 17.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marksans Pharma stock overvalued right now?
Based on GuruFocus' analysis, Marksans Pharma (BOM:524404) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹229.14, compared to a current price of ₹270.85 — trading 18.2% above its estimated fair value. The current Pretax Margin % is 23.36%, which is 34% above median its 10-year median of 17.49 and 220.9% above the Drug Manufacturers industry median of 7.28. Marksans Pharma's overall GF Score™ is 86/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Marksans Pharma (BOM:524404), the current Pretax Margin % is 23.36% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Marksans Pharma (BOM:524404) Overvalued in 2026?
Based on GuruFocus' analysis, Marksans Pharma stock appears to be overvalued.
The current stock price of ₹270.85 is trading 18.2% above its estimated GF Value™ of ₹229.14.
GuruFocus considers Marksans Pharma to be Modestly Overvalued.
Key valuation signals for BOM:524404:
Pretax Margin %: 23.36% (34% above median its 10-year median of 17.49)
GF Value™: ₹229.14 vs. price of ₹270.85 (18.2% above fair value)
Industry Position: 220.9% above the Drug Manufacturers median (#199 of 961)
No single metric tells the full story. See the BOM:524404 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Marksans Pharma Ltd is a pharmaceutical company. The company is engaged in the research, manufacturing, and marketing of pharmaceutical formulations. It manufactures analgesics, gastroenterology, anti-diabetic, cardiovascular, pain management, gynecology, gastrointestinal, and oncologic drugs as well as antibiotics and antiallergic medications. Geographically, the majority of its revenue is generated from the United States and North America, followed by Europe and the UK, Australia and New Zealand, and the Rest of the World.
86GF Score
Get the complete analysis for BOM:524404
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524404 has been successfully added to your 
